Filtered By:
Condition: Autoimmune Disease

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Complement C2 siRNA mediated therapy of myasthenia gravis in mice.
In this study, we show that inhibition of complement cascade activation by suppressing the expression of a critical low-abundant protein, C2, in the classical complement pathway, significantly improved clinical and immunopathological manifestations of EAMG. Two weeks after a second booster immunization with acetylcholine receptor, when mice exhibit muscle weakness, i.p. injection of C2 siRNA significantly suppressed C2 mRNA in the blood cells and liver of EAMG mice. Treatment of EAMG mice with C2 siRNA, once a week for 5 weeks, significantly improved muscle strength, which was further evidenced by functional AChR preservat...
Source: Journal of Autoimmunity - February 11, 2013 Category: Allergy & Immunology Authors: Huda R, Tüzün E, Christadoss P Tags: J Autoimmun Source Type: research

PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis
Conclusions: Hes-1 downregulation allows PDX-1 to act as a major determinant of cholangiocyte proliferation in response to cholestatic injury. These findings provide novel mechanistic insights into the pathophysiology of cholangiopathies.
Source: Journal of Hepatology - December 3, 2012 Category: Gastroenterology Authors: Marco Marzioni, Stefania Saccomanno, Laura Agostinelli, Chiara Rychlicki, Samuele De Minicis, Irene Pierantonelli, Michael Trauner, Peter Fickert, Tobias Müller, Kumar Shanmukhappa, Luciano Trozzi, Cinzia Candelaresi, Gianluca Svegliati Baroni, Antonio B Tags: Cholestasis and Autoimmune Diseases Source Type: research

MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats.
Abstract Rheumatoid arthritis (RA) is an autoimmune disease characterized by the rheumatoid factor and anti-citrullinated peptide antibody (ACPA) against common autoantigens that are widely expressed within and outside the joints. Many factors participate in the pathogenesis of RA, such as cytokine imbalance, Wnt pathway activation, matrix production, and osteoprotegerin on osteoclasts. Fibroblast-like synoviocytes (FLS) activation has an important role in RA pathogenesis. The methyl-CpG-binding protein (MeCP2) which promoted repressed chromatin structure was selectively detected in synovium of diseased articular ...
Source: Cellular Signalling - November 29, 2012 Category: Cytology Authors: Miao CG, Huang C, Huang Y, Yang YY, He X, Zhang L, Lv XW, Jin Y, Li J Tags: Cell Signal Source Type: research

Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remain significant issues. Without a solution to these delivery problems, RNAi cannot fulfill its therapeutic promise.Scientists at the National Institutes of Health, National Institute on Aging have d...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: ajoyprabhu3 Source Type: research

A Novel and Efficient Technology for Targeted Delivery of siRNA
The biological phenomenon of RNA interference (RNAi) has much promise for developing therapeutics to a variety of diseases. However, development of RNAi therapies remains mainly in preclinical stages largely because of difficulties in delivering small inhibitory RNAs (siRNA) and short hairpin RNAs (shRNA) into target cells. Although viral vector-based siRNA delivery systems have been widely used, their specificity and safety remains significant issue. Without a solution to this delivery problem, RNAi cannot fulfill its therapeutic promise. Investigators at the National Institutes of Health have developed novel compositions...
Source: NIH OTT Licensing Opportunities - January 1, 2009 Category: Research Authors: admin Source Type: research